Is the price fair?
What INNV's price assumes
InnovAge Holding Corp. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 1.15× revenue.
1.15
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 3.0%
Free cash flow yield · Medical Care Facilities median 7.1%
- Growth the price implies
- +12%
Growth the price implies · The price pays for +12% free cash flow growth a year for a decade; revenue has grown +12% a year over the last three.
- Price / book
- 4.75
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 4.75
- EV / EBIToperating margin −1.0%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 1.10
- Free cash flow, trailing twelve months
- $42M
- Market capitalisation
- $1.40B
- 3-year revenue growth
- +12%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.